Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.6K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Seizures: Classification01:13

Seizures: Classification

2.0K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.0K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.1K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

895
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
895
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.6K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurological manifestations in children with SARS-CoV-2 infection: a French multicentric cohort.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2025
Same author

Clinical trial knowledge in families of children with epilepsy. A survey from a French Center for Rare Epilepsies.

Revue neurologique·2025
Same author

Targeted therapies in epilepsies.

Revue neurologique·2025
Same author

Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study).

ESMO open·2024
Same author

mTOR-therapy and targeted treatment opportunities in mTOR-related epilepsies associated with cortical malformations.

Revue neurologique·2023
Same author

A simple novel approach for detecting blood-brain barrier permeability using GPCR internalization.

Neuropathology and applied neurobiology·2020

Related Experiment Video

Updated: Mar 14, 2026

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.8K

[Childhood absence epilepsy: An update].

P Garzon1, L Lemelle1, S Auvin1

  • 1Service de neurologie pédiatrique et des maladies métaboliques, CHU Robert-Debré, AP-HP, 48, boulevard Sérurier, 75019 Paris, France.

Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie
|September 30, 2016
PubMed
Summary
This summary is machine-generated.

Childhood absence epilepsy (CAE) is a common pediatric epilepsy. Early detection of neuropsychological issues and appropriate treatment, like ethosuximide, are crucial for managing CAE and preventing academic difficulties.

More Related Videos

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
10:46

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Published on: September 1, 2023

4.6K
Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

1.7K

Related Experiment Videos

Last Updated: Mar 14, 2026

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.8K
Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
10:46

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Published on: September 1, 2023

4.6K
Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

1.7K

Area of Science:

  • Neurology
  • Pediatrics
  • Epileptology

Background:

  • Childhood absence epilepsy (CAE) is a prevalent pediatric epilepsy syndrome, comprising 10% of all cases.
  • Absence seizures are the sole seizure type at diagnosis, often manageable in general pediatric settings.
  • While often self-limiting, CAE requires careful monitoring due to potential neuropsychological comorbidities.

Purpose of the Study:

  • To provide an updated overview of childhood absence epilepsy for pediatricians.
  • To highlight diagnostic criteria, treatment options, and the importance of neuropsychological assessment.
  • To discuss referral criteria for specialist care.

Main Methods:

  • Review of current literature and clinical guidelines.
  • Analysis of diagnostic approaches including electroencephalogram (EEG) and clinical evaluation.
  • Evaluation of treatment efficacy and side effect profiles of antiepileptic drugs.

Main Results:

  • Ethosuximide is recommended as first-line treatment, with valproate as second-line.
  • Approximately one-third of patients experience attention deficits.
  • A significant risk of academic difficulties and cognitive disorders exists, necessitating early detection.

Conclusions:

  • CAE management requires a comprehensive approach beyond seizure control, addressing cognitive and psychosocial outcomes.
  • Early identification of at-risk children can prevent underachievement and improve psychosocial adjustment.
  • Treatment selection should consider cognitive side effects, with specialist referral indicated for complex cases.